• No results found

University of Groningen Access to innovative medicines in a middle-income country Moye Holz, Daniela Denisse

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Access to innovative medicines in a middle-income country Moye Holz, Daniela Denisse"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Access to innovative medicines in a middle-income country

Moye Holz, Daniela Denisse

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Moye Holz, D. D. (2019). Access to innovative medicines in a middle-income country: The case of Mexico and cancer medicines. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Access to Innovative

Medicines in a

Middle-Income Country

The Case of Mexico and Cancer Medicines

(3)

Cover design and layout by Elisa Calamita, persoonlijkproefschrift.nl Printing: Ridderprint BV | www.ridderprint.nl

ISBN/EAN: 978-94-034-1533-8 (printed version)

ISBN/EAN: 978-94-034-1532-1 (electronic version)

Daniela D. Moye Holz

Access to Innovative Medicines in a Middle-Income Country. The Case of Mexico and Cancer Medicines.

Doctoral Dissertation, University of Groningen, the Netherlands.

The research presented in this thesis was carried out at the GZW Global Health – Public Health Research Department of the Research Institute SHARE of the Graduate School of Medical Sciences of the University of Groningen. This research was supported by the Consejo Nacional de Ciencia y Teconología (CONACYT), Mexico.

Copyright © 2019 Daniela D. Moye Holz

All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any way or by any means without the prior permission of the author, or when applicable, of the publishers of the scientific papers.

(4)

Access to Innovative Medicines in

a Middle-Income Country

The Case of Mexico and Cancer Medicines

PhD Thesis

to obtain the degree of PhD at the University of Groningen

on the authority of the Rector Magnificus Prof. E. Sterken

and in accordance with the decision by the College of Deans.

This thesis will be defended in public on

Wednesday 24 April 2019 at 16.15 hours

by

Daniela Denisse Moye Holz born on 1 March 1985

(5)

Supervisors Prof. H.V. Hogerzeil Prof. S.A. Reijneveld

Co-supervisor Dr. J.P. van Dijk Assessment Committee Prof. R.H. Henning Prof. H.G.M. Leufkens Prof. A. Figueras

(6)

Contents

Chapter 1. Introduction 9 1.1. Universal health coverage and access to healthcare for

non-communicable diseases – the case of cancer in low- and middle-income countries

10

1.2. Access to essential medicines and the case of innovative essential medicines

13

1.3. The health system and access to essential medicines in Mexico 15 1.4. Objective and research questions 21 Chapter 2. Policy approaches to improve availability and affordability of

medicines in Mexico – an example of a middle-income country

33

Chapter 3. The impact of price negotiations on public procurement prices and access to eight innovative cancer medicines in a middle-income country – the case of Mexico

57

Chapter 4. Access to innovative cancer medicines in a middle-income country - the case of Mexico

89

Chapter 5. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico

109

Chapter 6. Access to cancer medicines in public hospitals in Mexico: the view of stakeholders

133

Chapter 7. Discussion and Conclusions 155 7.1. Main Findings 156 7.2. Reflections on Main Findings 158 7.3. Methodological considerations 164 7.4. Policy Implications 169 7.5. Conclusions 177 Summary 183 Samenvatting 189 Resumen 197 Acknowledgements 205

Research Institute SHARE 213

(7)
(8)

“A bird sitting on a tree is never afraid of the branch breaking because her trust is not on the branch but on its own wings…” – Unknown. To my biggest role model, the most wonderful and loving mom - for this achievement is also yours. Thank you for giving me big strong wings.

And for the other great women that came before me: my grandmothers Catalina and Ana María.

(9)

Referenties

GERELATEERDE DOCUMENTEN

Therefore, the aim of this study was to assess the effect of the CCNPMIS negotiations on four aspects of prices of innovative cancer medicines: uniformity of procurement prices in

Total annual quantities of eight innovative essential cancer medicines procured in the Mexican public sector (SHI institutions and MoH) per insurance scheme (2010-2016)..

Objective: To assess the availability and affordability of essential cancer medicines in Mexico, and compare their prices (public procurement and patient prices) against those

Objective: The aim of this study is to obtain insight on access to cancer medicines’ components regarding selection, financing, and healthcare, procurement and supply

Access to innovative essential cancer medicines is incomplete and unequal in Mexico. The availability of essential cancer medicines remains lower than international

In Chapter 4, we described the differences in use, as a proxy of access, of innovative essential cancer medicines between various health insurance institutions and

Hoofdstuk 5 laat de bevindingen zien wat betreft de actuele beschikbaarheid, prijzen en betaalbaarheid van essentiële geneesmiddelen tegen kanker in publieke en

Para obtener una perspectiva general del acceso a medicamentos oncológicos esenciales en el sector público en México, el Capítulo 6 informa sobre la percepción de informantes